IceCure highlights ProSense data in Form 6-K

Accepted by SEC EDGAR 09/22/2025 - 08:35 AM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

IceCure Medical Ltd. submitted a Form 6-K reporting that it issued a press release on September 22, 2025 titled “IceCure’s ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented.” The press release, excluding its second paragraph, is attached as an exhibit and describes positive clinical results for the company’s ProSense cryoablation technology from four independent studies presented at the CIRSE 2025 annual meeting. The company is also incorporating this press release by reference into several of its existing Form F-3 and Form S-8 registration statements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IceCure Medical Ltd. (ICCM) report in this Form 6-K?

IceCure Medical Ltd. reported that it issued a press release on September 22, 2025 titled “IceCure’s ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented,” and furnished that press release as an exhibit.

What is highlighted about IceCure’s ProSense system in this filing?

The filing notes that the ProSense® cryoablation system was featured at the CIRSE 2025 annual meeting, with positive clinical results reported from four independent studies as described in the attached press release.

How many independent studies on ProSense are mentioned by IceCure (ICCM)?

The title of the press release states that positive clinical results with cryoablation came from 4 independent studies presented at the CIRSE 2025 annual meeting.

How is the September 22, 2025 press release used in IceCure’s SEC registrations?

The press release attached as Exhibit 99.1, excluding its second paragraph, is incorporated by reference into IceCure’s Registration Statements on Form F-3 (Nos. 333-258660, 333-267272 and 333-290046) and Form S-8 (Nos. 333-270982, 333-264578, 333-262620 and 333-281587).

Does this IceCure (ICCM) Form 6-K involve any new securities offerings?

The Form 6-K describes the furnishing of a press release and its incorporation by reference into existing Form F-3 and Form S-8 registration statements; it does not describe new securities offering terms in the provided content.

Who signed this IceCure Medical Ltd. Form 6-K?

The Form 6-K was signed on behalf of IceCure Medical Ltd. by Eyal Shamir, Chief Executive Officer, dated September 22, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: September 2025 (Report No. 5)

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

CONTENTS

On September 22, 2025, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure’s ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K.

The press release attached herewith as Exhibit 99.1 (excluding the second paragraph thereof) is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-258660, 333-267272 and 333-290046) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.
99.1		Press release dated September 22, 2025 titled “IceCure’s ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ICECURE MEDICAL LTD.

Date: September 22, 2025	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR